Patents by Inventor Hye Jin HEO

Hye Jin HEO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11572341
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: February 7, 2023
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo Kim, Jae Kap Jeong, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Sung Wuk Kim
  • Patent number: 11465989
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: October 11, 2022
    Assignee: ImmunoMet Therapeutics, Inc.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee, Mi Jeong Kim, Woong Cho
  • Publication number: 20200277255
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 3, 2020
    Inventors: Hong Woo KIM, Jae Kap JEONG, Ji Sun LEE, Hye Jin HEO, Hong Bum LEE, Ji Ae KOOK, Sung Wuk KIM
  • Patent number: 10626085
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: April 21, 2020
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo Kim, Jae Kap Jeong, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Sung Wuk Kim
  • Patent number: 10590081
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 17, 2020
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee
  • Publication number: 20190144464
    Abstract: The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.
    Type: Application
    Filed: January 10, 2019
    Publication date: May 16, 2019
    Inventors: Hong Woo Kim, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Jae Kap Jeong, Ji Hyun Park, Seo-il Kim, Young Woo Lee
  • Patent number: 10252996
    Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 9, 2019
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Chang Hee Min, Yong Eun Kim, Byung Kyu Oh, Ji Sun Lee, Hye Jin Heo, Ju Hoon Oh, Woong Cho
  • Patent number: 10221190
    Abstract: The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: March 5, 2019
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo Kim, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Jae Kap Jeong, Ji Hyun Park, Seo-il Kim, Young Woo Lee
  • Patent number: 10058558
    Abstract: The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: August 28, 2018
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Sung Wuk Kim, Soon Im Lee, Yeon Jung Song, Min Jae Shin, Kook Hwan Oh, Kyung Don Ju, Eun Kyoung Shin, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Min Jeong Kim, Hye Soun Eum
  • Publication number: 20180105494
    Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 19, 2018
    Inventors: Chang Hee MIN, Yong Eun KIM, Byung Kyu OH, Ji Sun LEE, Hye Jin HEO, Ju Hoon OH, Woong CHO
  • Publication number: 20180093953
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Application
    Filed: April 30, 2015
    Publication date: April 5, 2018
    Inventors: Sung Wuk KIM, Hong Woo KIM, Sang Hee YOO, Ji Sun LEE, Hye Jin HEO, Hong Bum LEE, Ji Ae KOOK, Young Woo LEE
  • Publication number: 20180044283
    Abstract: The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.
    Type: Application
    Filed: November 20, 2015
    Publication date: February 15, 2018
    Applicant: ImmunoMet Therapeutics Inc.
    Inventors: Hong Woo KIM, Jae Kap JEONG, Ji Sun LEE, Hye Jin HEO, Hong Bum LEE, Ji Ae KOOK, Sung Wuk KIM
  • Patent number: 9884821
    Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: February 6, 2018
    Assignee: ImmunoMet Therapeutics Inc.
    Inventors: Chang Hee Min, Yong Eun Kim, Byung Kyu Oh, Ji Sun Lee, Hye Jin Heo, Ju Hoon Oh, Woong Cho
  • Publication number: 20170305861
    Abstract: The present invention relates to heteroaryl compounds comprising nitrogen and use thereof, and more specifically to compounds which exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compounds according to the present invention exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer with a reduced dose compared to that of existing drugs. Accordingly, the compounds can be effectively used for treating various types of cancer, such as uterine cancer, breast cancer, gastric cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, and liver cancer, and for inhibiting proliferation of cancer cells and metastasis of cancer.
    Type: Application
    Filed: April 25, 2017
    Publication date: October 26, 2017
    Applicant: ImmunoMet Therapeutics, Inc
    Inventors: Sung Wuk Kim, Hong Woo Kim, SangHee Yoo, Hyunwook Kim, Hye Jin Heo, Hong Bum Lee, Jiae Kook, Young Woo Lee
  • Patent number: 9630977
    Abstract: The present invention relates to novel cephalosporin derivatives represented by X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: April 25, 2017
    Assignee: Legochem Biosciences, Inc.
    Inventors: Young Lag Cho, Joung Yul Yun, Sang Eun Chae, Chul Soon Park, Hyang Sook Lee, Kyu Man Oh, Hye Jin Heo, Dae Hyuck Kang, Young Jae Yang, Hyun Jin Kwon, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
  • Publication number: 20170073331
    Abstract: The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.
    Type: Application
    Filed: April 17, 2015
    Publication date: March 16, 2017
    Applicant: IMMUNOMET THERAPEUTICS INC.
    Inventors: Sung Wuk Kim, Hong Woo Kim, Sang Hee Yoo, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Young Woo Lee, Mi Jeong Kim, Woong Cho
  • Publication number: 20160101112
    Abstract: The present invention provides a novel use of N1-cyclic amine-N5-substituted biguanide derivatives for preparing a medicine for preventing or treating fibrosis. The N1-cyclic amine-N5-substituted biguanide derivatives according to the present invention are capable of effectively inhibiting fibrosis by effectively suppressing the EMT.
    Type: Application
    Filed: May 20, 2014
    Publication date: April 14, 2016
    Applicant: IMMUNOMET THERAPEUTICS INC
    Inventors: Sung Wuk Kim, Soon Im Lee, Yeon Jung Song, Min Jae Shin, Kook Hwan Oh, Kyung Don Ju, Eun Kyoung Shin, Ji Sun Lee, Hye Jin Heo, Hong Bum Lee, Ji Ae Kook, Min Jeong Kim, Hye Soun Eum
  • Publication number: 20150368198
    Abstract: The present invention provides an N1-cyclic amine-N5-substituted biguanide derivative compound represented by Formula 1, a method of preparing the same and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient. The biguanide derivatives have an effect of inhibiting cancer cell proliferation, cancer metastasis and cancer recurrence by activation of AMPK, even when administered in a small dose compared with conventional drugs.
    Type: Application
    Filed: February 6, 2014
    Publication date: December 24, 2015
    Inventors: Chang Hee MIN, Yong Eun KIM, Byung Kyu OH, Ji Sun LEE, Hye Jin HEO, Ju Hoon OH, Woong CHO
  • Publication number: 20150126518
    Abstract: The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: May 7, 2015
    Applicant: HANALL BIOPHARMA CO., LTD.
    Inventors: Hong Woo KIM, Ji Sun LEE, Hye Jin HEO, Hong Bum LEE, Jae Kap JEONG, Ji Hyun PARK, Seo-il KIM, Young Woo LEE
  • Patent number: 8846669
    Abstract: Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: September 30, 2014
    Assignee: Legochem Biosciences, Inc.
    Inventors: Young Lag Cho, Sung Yoon Baek, Sang Eun Chae, Sun Young Kim, Hong Bum Lee, Hyang Sook Lee, Kyuman Oh, Hye Jin Heo, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim